The Cancer Commons/Musella Foundation study of combination therapy regimens aims to improve patient outcomes and identify promising therapies for development.
MOUNTAIN VIEW, California, USA, Aug. 12, 2022 /EINPresswire.com/ — Cancer Commons, a nonprofit organization that supports advanced cancer patients and their caregivers, and the Musella Foundation for Research and Brain Tumor Information, Inc., a nonprofit organization dedicated to helping brain tumor patients and raising funds for research, today announced the launch of a multi-party collaboration aimed at improving outcomes for current patients and to identify promising therapies for development. This pilot health learning system will use genomic sequencing and other biomarkers to recommend individualized treatment regimens and capture and analyze clinical outcomes to inform treatment for future patients.
While many common cancers have seen significant reductions in mortality rates, despite decades of research, brain tumors remain among the deadliest of all forms of cancer. Glioblastoma is the most common primary brain cancer, with approximately 12,000 cases diagnosed each year in the United States. The median survival time after diagnosis is 15 to 18 months, while the five-year survival rate for the disease is around 10%. All glioblastomas are grade IV brain tumors, and all will eventually recur.
Patients who don’t respond to traditional therapies are usually referred to a clinical trial, but eligibility criteria and geography rule out the majority, so few have good options. There is a huge need to study targeted anticancer drugs that have shown sustained responses in various combinations. Studying individualized combinations has the potential to find what works much faster than large clinical trials, which are usually locked into a single hypothesis.
The new Cancer Commons/Musella Foundation project will integrate clinical care, research and patient outcomes to investigate individualized treatment regimens to optimize each patient’s outcome. Promising regimens can then be rapidly replicated in a small cohort of similar patients, which may facilitate streamlined integration into prospective interventional clinical trials.
“Our goal is to create a multi-stakeholder ecosystem of expertise, access and support to provide brain tumor patients with the latest testing and treatment options, and to continuously learn from their experiences,” said Marty Tenenbaum, PhD, Founder of Cancer Commons. “By using personalized drug combinations, we believe it is possible to dramatically change patient outcomes by determining the right combination of therapies for the right patients.”
“We are proud to fund this promising pilot project, which we believe can lay the groundwork for significant progress,” said Musella Foundation founder Al Musella, DPM. “Our goals for the pilot project are to help physicians use individualized regimens of tests and therapies to improve patient outcomes, and to demonstrate to the oncology community the feasibility of a learning healthcare system that is constantly learning. from real-world evidence.”
Cancer Commons and the Musella Foundation invite other nonprofits and industry stakeholders to join in future phases of this project.
About Cancer Commons
Cancer Commons (cancercommons.org) is a patient-centered 501(c)(3) nonprofit organization whose compassionate experts connect with advanced cancer patients and caregivers to create life-saving plans. custom actions. Their navigator nurses, doctoral students and national experts consult the latest and most promising research to identify, explain and help patients access the best possible diagnostic and treatment options, so that they can be sure to take the best possible decisions.
About the Musella Foundation for Brain Tumor Research
The Musella Foundation (virtualtrials.org) is a 501(c)(3) public non-profit charitable organization dedicated to helping brain tumor patients through emotional and financial support, education , advocacy and fundraising for brain tumor research.
write to us here
Visit us on social media: